Octapharma USA has announced that wilate, the first replacement therapy development specifically for von Willebrand Disease (VWD), is now available from the biopharmaceutical company’s authorized distributors. The FDA has approved wilate for the treatment of spontaneous or trauma-induced bleeding episodes in patients with severe VWD as well as in patients with mild or moderate forms of the illness in whom the use of desmopressin is known or suspected to be ineffective or contraindicated.
“Wilate is an innovative treatment option for patients with von Willebrand disease that offers a high purity VWF/FVIII complex with a physiologic ratio of FVIII and VWF, double virus inactivation, convenient dosing, and clinical efficacy, safety, and tolerability proven in adult and pediatric populations,” said Flemming Nielsen, President of Octapharma USA, the rapidly growing U.S. division of Octapharma AG, one of the largest plasma products manufacturers in the world. “We are pleased to be partnering with distributors who are committed to providing medical professionals with the therapies patients need in a timely, cost-effective manner.”
